The director of Sturm, Ruger & Company, Inc. (RGR), Sandra Froman Invested in 100 Shares of the Company; Vanda Pharmaceuticals Inc. (VNDA) Had 8 Analysts Last Week

The director of Sturm Ruger & Co Inc, Sandra Froman is in the stock market news today. It was made public in a form filled by Sandra Froman and submitted to the SEC on 01/03/2018, she bought 100 shares from the firm having a value near $4,500 US Dollars. The transaction’s shares average price was $45.0. And, It’s sure Sandra’s trade isn’t going to stay undiscovered as she currently is possessing 4,879 shares – ( 0.03% of Sturm Ruger & Co Inc’s Market Cap ).

Among 8 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vanda Pharmaceuticals had 22 analyst reports since September 2, 2015 according to SRatingsIntel. Jefferies reinitiated Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Thursday, October 6 with “Buy” rating. The firm has “Buy” rating given on Wednesday, September 2 by Piper Jaffray. The firm has “Buy” rating given on Sunday, November 12 by Oppenheimer. The rating was maintained by Jefferies on Monday, September 4 with “Buy”. On Thursday, October 19 the stock rating was maintained by Piper Jaffray with “Buy”. Oppenheimer maintained the stock with “Buy” rating in Thursday, August 3 report. Brean Capital initiated the shares of VNDA in report on Wednesday, October 21 with “Buy” rating. The stock has “Buy” rating by H.C. Wainwright on Thursday, August 3. JMP Securities maintained it with “Market Outperform” rating and $18 target in Wednesday, March 9 report. Oppenheimer maintained the shares of VNDA in report on Monday, January 8 with “Buy” rating. See Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) latest ratings:

13/02/2018 Broker: Jefferies Rating: Buy New Target: $20.0 Maintain
19/01/2018 Broker: Seaport Global Rating: Buy New Target: $20 Initiates Coverage On
08/01/2018 Broker: Oppenheimer Rating: Buy Maintain
12/11/2017 Broker: Oppenheimer Rating: Buy New Target: $25.0 Maintain
30/10/2017 Broker: Oppenheimer Rating: Outperform Old Target: $21 New Target: $26 Maintain
19/10/2017 Broker: Piper Jaffray Rating: Buy New Target: $26.0 Maintain
04/09/2017 Broker: Jefferies Rating: Buy New Target: $21.0 Maintain

The stock decreased 0.80% or $0.15 during the last trading session, reaching $18.7. About 676,262 shares traded or 15.34% up from the average. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 51.60% since March 2, 2017 and is uptrending. It has outperformed by 34.90% the S&P500.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company has market cap of $849.69 million. The companyÂ’s marketed products include HETLIOZ , a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. It currently has negative earnings. The Company’s clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

Since January 2, 2018, it had 0 insider buys, and 4 insider sales for $3.36 million activity. Kelly James Patrick had sold 9,155 shares worth $140,494. Shares for $2.93 million were sold by Polymeropoulos Mihael Hristos. 10,367 shares valued at $157,565 were sold by Gulino Richard L. on Tuesday, January 2. Birznieks Gunther sold 8,568 shares worth $130,777.

Investors sentiment increased to 1.43 in 2017 Q3. Its up 0.26, from 1.17 in 2017Q2. It improved, as 12 investors sold Vanda Pharmaceuticals Inc. shares while 34 reduced holdings. 21 funds opened positions while 45 raised stakes. 38.89 million shares or 4.39% more from 37.25 million shares in 2017Q2 were reported. Cap One Association invested in 18,890 shares. 423,884 were reported by Baker Bros Advisors Limited Partnership. Kistler reported 200 shares. Weiss Multi has invested 0.04% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Renaissance Ltd Liability Corp reported 1.22 million shares or 0.03% of all its holdings. Dekabank Deutsche Girozentrale reported 0% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Northern Trust holds 591,786 shares or 0% of its portfolio. 38,075 were reported by Matarin Cap Management Llc. Balyasny Asset Limited Liability Corporation owns 0% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 21,900 shares. Cadence Capital Lc accumulated 62,606 shares. Axiom Int Ltd Co De accumulated 137,167 shares. Perceptive Limited has invested 0.02% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Point72 Asset Mgmt Lp holds 0.01% or 100,000 shares in its portfolio. Cortina Asset Lc accumulated 212,503 shares or 0.16% of the stock. Amer International Group Inc Incorporated reported 29,526 shares.

Sturm, Ruger & Company, Inc. designs, makes, and sells firearms under the Ruger name and trademark in the United States. The company has market cap of $787.71 million. It operates in two divisions, Firearms and Castings. It has a 15.53 P/E ratio. The firm offers single-shot, autoloading, bolt-action, and sporting rifles; rimfire and centerfire autoloading pistols; single-action and double-action revolvers; and firearms accessories and replacement parts.

Among 4 analysts covering Sturm Ruger (NYSE:RGR), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Sturm Ruger has $68 highest and $51 lowest target. $65.25’s average target is 44.36% above currents $45.2 stock price. Sturm Ruger had 7 analyst reports since July 24, 2015 according to SRatingsIntel. The stock of Sturm, Ruger & Company, Inc. (NYSE:RGR) earned “Buy” rating by Dougherty & Company on Thursday, February 25. The firm has “Buy” rating by BB&T Capital given on Friday, July 24. The rating was downgraded by BB&T Capital on Monday, June 6 to “Hold”. The stock of Sturm, Ruger & Company, Inc. (NYSE:RGR) earned “Sell” rating by KeyBanc Capital Markets on Tuesday, August 4.

The stock increased 4.99% or $2.15 during the last trading session, reaching $45.2. About 529,889 shares traded or 76.21% up from the average. Sturm, Ruger & Company, Inc. (NYSE:RGR) has declined 1.80% since March 2, 2017 and is downtrending. It has underperformed by 18.50% the S&P500.

Investors sentiment decreased to 1.05 in 2017 Q3. Its down 0.10, from 1.15 in 2017Q2. It worsened, as 37 investors sold Sturm, Ruger & Company, Inc. shares while 46 reduced holdings. 27 funds opened positions while 60 raised stakes. 14.25 million shares or 2.06% more from 13.96 million shares in 2017Q2 were reported. Deprince Race Zollo Inc stated it has 92,777 shares or 0.11% of all its holdings. Gemmer Asset Ltd invested 0% of its portfolio in Sturm, Ruger & Company, Inc. (NYSE:RGR). Contravisory Inv Mngmt holds 27 shares or 0% of its portfolio. Morgan Dempsey Mngmt Lc stated it has 119,513 shares. Schwab Charles Inv reported 128,347 shares stake. Art Advsrs Ltd Co reported 18,446 shares. Alps Advisors invested 0% in Sturm, Ruger & Company, Inc. (NYSE:RGR). Great West Life Assurance Can reported 24,012 shares stake. Pinebridge Investments L P has invested 0.02% of its portfolio in Sturm, Ruger & Company, Inc. (NYSE:RGR). Comerica Natl Bank stated it has 0.01% of its portfolio in Sturm, Ruger & Company, Inc. (NYSE:RGR). Atria Ltd Limited Liability Company has invested 0.01% in Sturm, Ruger & Company, Inc. (NYSE:RGR). Renaissance Technology Ltd Liability has invested 0.01% in Sturm, Ruger & Company, Inc. (NYSE:RGR). Commonwealth Equity Services has 17,692 shares. James invested in 0% or 225 shares. Ent reported 289 shares stake.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: